{"id":5798,"date":"2025-02-28T21:32:38","date_gmt":"2025-02-28T18:32:38","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=5798"},"modified":"2025-02-28T21:32:38","modified_gmt":"2025-02-28T18:32:38","slug":"summary-alternative-access-options-for-tavr","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/summary-alternative-access-options-for-tavr\/","title":{"rendered":"Summary: Alternative Access Options for TAVR"},"content":{"rendered":"<div>Summary: Alternative Access Options for TAVR<\/div>\n<div><\/div>\n<div>February 25, 2025<\/div>\n<div>Reference: SCAI Expert Consensus Statement on Alternative Access for Transcatheter Aortic Valve Replacement (JSCAI)<\/div>\n<div><\/div>\n<div>Key Points:<\/div>\n<div><span class=\"Apple-tab-span\"> <\/span>\u2022<span class=\"Apple-tab-span\"> <\/span>Why Alternative Access?<\/div>\n<div><span class=\"Apple-tab-span\"> <\/span>\u2022<span class=\"Apple-tab-span\"> <\/span>Transfemoral access is the preferred route for TAVR but is not always feasible due to patient anatomy or comorbidities.<\/div>\n<div><span class=\"Apple-tab-span\"> <\/span>\u2022<span class=\"Apple-tab-span\"> <\/span>The Society for Cardiovascular Angiography &amp; Interventions (SCAI) released expert recommendations for alternative access methods.<\/div>\n<div><span class=\"Apple-tab-span\"> <\/span>\u2022<span class=\"Apple-tab-span\"> <\/span>Preferred Alternative Access Methods:<\/div>\n<div><span class=\"Apple-tab-span\"> <\/span>\u2022<span class=\"Apple-tab-span\"> <\/span>Transcarotid and transcaval access are the best alternatives due to lower stroke risk and better patient outcomes.<\/div>\n<div><span class=\"Apple-tab-span\"> <\/span>\u2022<span class=\"Apple-tab-span\"> <\/span>Transaxillary access is less favored.<\/div>\n<div><span class=\"Apple-tab-span\"> <\/span>\u2022<span class=\"Apple-tab-span\"> <\/span>Transapical and direct aortic access are not recommended due to higher risks.<\/div>\n<div><span class=\"Apple-tab-span\"> <\/span>\u2022<span class=\"Apple-tab-span\"> <\/span>Expert Insights:<\/div>\n<div><span class=\"Apple-tab-span\"> <\/span>\u2022<span class=\"Apple-tab-span\"> <\/span>Dr. Matthew W. Sherwood:<\/div>\n<div><span class=\"Apple-tab-span\"> <\/span>\u2022<span class=\"Apple-tab-span\"> <\/span>Despite device advancements, TAVR patients without femoral access need safe, standardized techniques.<\/div>\n<div><span class=\"Apple-tab-span\"> <\/span>\u2022<span class=\"Apple-tab-span\"> <\/span>Alternative access options are especially important for older, high-risk patients with vascular disease.<\/div>\n<div><span class=\"Apple-tab-span\"> <\/span>\u2022<span class=\"Apple-tab-span\"> <\/span>Dr. Paul D. Mahoney:<\/div>\n<div><span class=\"Apple-tab-span\"> <\/span>\u2022<span class=\"Apple-tab-span\"> <\/span>TAVR is now a standard of care, and these guidelines help clinicians choose best practices for optimal patient outcomes.<\/div>\n<div><span class=\"Apple-tab-span\"> <\/span>\u2022<span class=\"Apple-tab-span\"> <\/span>Looking Ahead:<\/div>\n<div><span class=\"Apple-tab-span\"> <\/span>\u2022<span class=\"Apple-tab-span\"> <\/span>The consensus calls for further research into newer techniques like intravascular lithotripsy to refine TAVR access methods.<\/div>\n<div><\/div>\n<div>Conclusion:<\/div>\n<div>These updated SCAI recommendations provide a structured approach for TAVR specialists, ensuring safer, more effective alternative access for patients who cannot undergo transfemoral TAVR.<\/div>\n<div><\/div>\n<div><a href=\"https:\/\/www.jscai.org\/article\/S2772-9303(24)02203-8\/fulltext\">https:\/\/www.jscai.org\/article\/S2772-9303(24)02203-8\/fulltext<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Summary: Alternative Access Options for TAVR February 25, 2025 Reference: SCAI Expert Consensus Statement on Alternative Access for Transcatheter Aortic Valve Replacement (JSCAI) Key Points: \u2022 Why Alternative Access? \u2022 Transfemoral access is the preferred route for TAVR but is not always feasible due to patient anatomy or comorbidities. \u2022 The Society for Cardiovascular Angiography [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-5798","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/5798","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=5798"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/5798\/revisions"}],"predecessor-version":[{"id":5799,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/5798\/revisions\/5799"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=5798"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=5798"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=5798"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}